Tumor-specific neoepitopes are promising targets in cancer immunotherapy. However, the identification of functional tumor-specific neoepitopes remains challenging. In addition to the most common source, single-nucleotide variants (SNV), alternative splicing (AS) represents another rich source of neoepitopes and can be utilized in cancers with low SNVs such as uveal melanoma (UM). UM, the most prevalent adult ocular malignancy, has poor clinical outcomes due to a lack of effective therapies. Recent studies have revealed the promise of harnessing tumor neoepitopes to treat UM. Previous studies have focused on neoepitope targets associated with mutations in splicing factor 3b subunit 1 (SF3B1), a key splicing factor; however, little is known about the neoepitopes that are commonly shared by patients independent of SF3B1 status. To identify the AS-derived neoepitopes regardless of SF3B1 status, we herein used a comprehensive nanopore long-read-sequencing approach to elucidate the landscape of AS and novel isoforms in UM. We also performed high-resolution mass spectrometry to further validate the presence of neoepitope candidates and analyzed their structures using the AlphaFold2 algorithm. We experimentally evaluated the antitumor effects of these neoepitopes and found they induced robust immune responses by stimulating interferon (IFN)γ production and activating T cell–based UM tumor killing. These results provide novel insights into UM-specific neoepitopes independent of SF3B1 and lay the foundation for developing therapies by targeting these actionable neoepitopes.
AT-rich interaction domain 1A (ARID1A) is a crucial subunit of the switch/sucrose nonfermentable (SWI/SNF) chromatin-remodeling complex and the ARID1A gene is frequently mutated in human cancers. Although its tumor-suppressive activity has been ascribed exclusively to SWI/SNF-dependent chromatin remodeling, we established in this study a SWI/SNF-independent role of ARID1A in safeguarding heterochromatin architecture to silence viral mimicry and restrain immunogenicity in colorectal cancer. ARID1A deficiency triggered viral mimicry and enhanced immunogenicity in both microsatellite-stable and -instable contexts. Mechanistically, ARID1A interacted with TRIM28 to preserve heterochromatin rigidity. Loss of ARID1A protein displaced SETDB1 from the TRIM28-containing heterochromatin complex, leading to the reversal of H3K9me3-mediated repression at endogenous retroelement regions. The release of these elements triggered viral mimicry, exemplified by enhanced type I IFN-mediated immune responses. Notably, disrupting the ARID1A–TRIM28 interaction with synthetic peptides induced a viral mimicry phenotype in ARID1A wild-type tumors, converting immunologically “cold” lesions into T cell–inflamed microenvironments and suppressing tumor growth. Both cytosolic RNA and DNA sensors were required for the ensuing IFN response and for the heightened sensitivity to PD-1 blockade elicited by ARID1A deficiency. These findings thus reveal an unanticipated heterochromatin gatekeeper function of ARID1A that operates outside the SWI/SNF complex and can be exploited to potentiate immune checkpoint therapy activity. Significance: Loss of ARID1A disrupts heterochromatin architecture and induces viral mimicry and immunogenicity in a TRIM28-dependent but SWI/SNF-independent manner, highlighting the potential of targeting the ARID1A-TRIM28 axis to improve immunotherapy efficacy.
Significant progress in the application of immune checkpoint blockade (ICB) for the treatment of multiple types of cancers has been achieved, but its overall response rate and therapeutic efficacy remain unsatisfactory. To address these limitations, the identification of a combinational approach to enhance the therapeutic efficacy of ICB is needed. The activation of cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) signaling is critical to the induction of antitumor innate immune responses and is a promising target for the development of combinational immunotherapy. Here, through the Connectivity Map database and a kinase inhibitor library screen using interferon-stimulated genes (ISGs) as a functional readout, we identified PIKfyve as a negative regulator of cGAS-STING signaling. The inhibition of PIKfyve by the kinase inhibitor YM201636, or genetic ablation elicited the expression of ISGs downstream of cGAS-STING and reshapes the antitumor microenvironment by recruiting CD8+ T lymphocytes. In melanoma models, PIKfyve inhibition conferred sensitivity to the combinational therapy of cisplatin and anti-PD1, which lead to a durable treatment response. Depletion of Sting or CD8+ T cells in B16F10 tumor significantly weakened the synergistic effect of PIKfyve inhibition and cisplatin. Mechanistically, PIKfyve interacts with STING to facilitate its trafficking from endosome to lysosome for degradation, thereby suppressing the STING-signaling mediated antitumor activity. These results highlight the importance of maintaining STING signaling as a direction to augment the efficacies of combinational immunotherapies.